AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction

Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the alpha-galactosidase A (GLA) gene, which encodes the exogalactosyl hydrolase, alpha-galactosidase A (α-Gal A). Deficient α-Gal A activity results in the progressive, systemic accumulation of its substrates, globotriaos...

Descripción completa

Detalles Bibliográficos
Autores principales: Yasuda, Makiko, Huston, Marshall W., Pagant, Silvere, Gan, Lin, St. Martin, Susan, Sproul, Scott, Richards, Daniel, Ballaron, Stephen, Hettini, Khaled, Ledeboer, Annemarie, Falese, Lillian, Cao, Liching, Lu, Yanmei, Holmes, Michael C., Meyer, Kathleen, Desnick, Robert J., Wechsler, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396970/
https://www.ncbi.nlm.nih.gov/pubmed/32775495
http://dx.doi.org/10.1016/j.omtm.2020.07.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396970/
https://www.ncbi.nlm.nih.gov/pubmed/32775495
http://dx.doi.org/10.1016/j.omtm.2020.07.002

Ejemplares similares